Forge Biologics to Participate in Upcoming Investor Conferences and Presentations in March 2022
COLUMBUS, Ohio--(BUSINESS WIRE)--#genetherapy--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that members of the Company’s leadership team will be participating at the following upcoming investor conferences in March:
Cowen 42nd Annual Virtual Health Care Conference |
||
Dates: |
March 7-9, 2022 |
|
Format: |
1x1 investor meetings |
|
|
|
|
Oppenheimer Fireside Chat |
||
Date: |
March 14, 2022 |
|
Time: |
11:00 a.m. Eastern Time |
|
Title: |
“AAV-based Gene Therapy: Navigating Regulatory and CMC Landscape” |
|
Presenters: |
Timothy J. Miller, Ph.D., Chief Executive Officer of Forge Biologics |
|
|
RA Session, II, Chief Executive Officer of Taysha Gene Therapies |
|
|
Rachel Potter, Ph.D., Head of Gene Therapy Research at Sarepta Therapeutics |
|
Moderators: |
Kevin DeGeeter, Senior Analyst, Biotechnology and Diagnostics |
|
|
Hartaj Singh, Senior Analyst, Biotechnology |
|
|
|
|
Oppenheimer 32nd Annual Virtual Healthcare Conference |
||
Dates: |
March 15-17, 2022 |
|
Format: |
1x1 investor meetings |
|
|
|
|
Date: |
March 17, 2022 |
|
Time: |
10:40 a.m. Eastern Time |
|
Format: |
Company presentation |
|
Presenter: |
Timothy J. Miller, Ph.D., CEO, President and Co-Founder of Forge Biologics |
|
Dr. Miller’s Oppenheimer company presentation will be delivered via live webcast and may be accessed for 90 days by visiting Forge’s Events website at https://www.forgebiologics.com/news/#events.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 200,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.
Contacts
Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com
Business Development
Magdalena Tyrpien
Senior Vice President, Head of Business Development
BD@forgebiologics.com
Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com
Investor Relations
Christina Perry
Senior Vice President, Finance and Investor Relations
Investors@forgebiologics.com
Editor Details
-
Company:
- Businesswire
